ARQT News and Press, Arcutis Biotherapeutics Inc. From 09/19/23

Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials For the primary endpoint, 25.4% of children treated once daily with roflumilast cream 0.05% achieved Investigator Global Assessment (IGA) S...

Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States In pivotal Phase 3 trials, roflumilast cream demonstrated statistically significant improvements over vehicle on the primary endpoint of Investigator ...

2023-09-07 15:08:31 ET Shares of Arcutis Biotherapeutics (NASDAQ: ARQT) were down 15.7% for the week as of 2:45 p.m. on Thursday, according to data provided by S&P Global Market Intelligence . The healthcare company's stock closed last week at $8.96 a share and fell to a...

Results for adults and children ages 6 years and older from INTEGUMENT-OLE long-term extension trial highlight that 46.1% and 51.0% of patients who rolled over from the roflumilast cream treatment arm in INTEGUMENT-1 or -2 achieved IGA success at Week 28 and Week 56, respectively Roflumilast ...

2023-08-31 10:33:45 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Here’s a look at 3 biotech short squeeze candidates. For investors looking for short-term gains, technical analysis provides key insights on potential entry and exit points. However, ove...

Company shows advancement toward improving patient care, access and affordability, social capital, drug safety, sustainability, and ethical business practices WESTLAKE VILLAGE, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage ...

The Cream That Can is a direct-to-consumer ad highlighting that clear skin is possible with ZORYVE ZORYVE is a once-daily, steroid-free cream for individuals with plaque psoriasis 12 years and above that can be used for long-term treatment across all affected areas of the body ZORYVE ...

2023-08-21 13:08:17 ET Gainers: Timber Pharmaceuticals ( TMBR ) +97% . China SXT Pharmaceuticals ( SXTC ) +92% . Novo Integrated Sciences ( NVOS ) +43% . Orchestra BioMed Holdings ( OBIO ) +27% . AlloVir ( ALVR ) +26% . The G...

2023-08-21 11:52:45 ET More on Health Care Select Sector SPDR XLV Vs. VHT: A Head-To-Head Healthcare ETF Comparison XLV: The Powerhouse ETF Driving Health And Wealth BlackRock spotlights healthcare as an opportunity with recession talks in the air Goldman add...

2023-08-20 03:50:00 ET Summary Jiangsu Hengrui Pharma out-licensed global rights for an anti-inflammatory drug to ONE Bio in a $1 billion deal. Shanghai Sangon Biotech raised $290 million in funding from private investors. Hangzhou Zhongmei Huadong Pharma in-licensed China-SE ...